IO Biotech, Inc. (IOBT)
NASDAQ: IOBT · IEX Real-Time Price · USD
1.730
-0.020 (-1.14%)
At close: Mar 28, 2024, 3:59 PM
1.800
+0.070 (4.05%)
After-hours: Mar 28, 2024, 6:49 PM EDT
IO Biotech Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for IO Biotech stock have an average target of 8.33, with a low estimate of 7.00 and a high estimate of 10. The average target predicts an increase of 381.50% from the current stock price of 1.73.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for IO Biotech stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +362.43% | Mar 6, 2024 |
Piper Sandler | Piper Sandler | Buy Initiates $10 | Buy | Initiates | $10 | +478.03% | Sep 28, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +362.43% | Sep 13, 2023 |
Morgan Stanley | Morgan Stanley | Buy Maintains $11 → $7 | Buy | Maintains | $11 → $7 | +304.62% | Aug 15, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 → $8 | Strong Buy | Reiterates | $11 → $8 | +362.43% | Aug 11, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
1.02M
EPS This Year
-1.71
from -1.98
EPS Next Year
-1.49
from -1.71
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | 6.3M | 32.7M | 137.5M | 256.1M |
Avg | n/a | 1.0M | 25.3M | 94.0M | 188.2M |
Low | n/a | n/a | 13.3M | 60.0M | 122.8M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | 3,101.5% | 444.0% | 172.6% |
Avg | - | - | 2,378.1% | 271.8% | 100.3% |
Low | - | - | 1,199.2% | 137.5% | 30.7% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -1.19 | -1.18 | -1.19 | -0.65 | 0.21 |
Avg | -1.71 | -1.49 | -1.22 | -0.83 | -0.27 |
Low | -2.63 | -1.58 | -1.27 | -0.99 | -0.49 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.